GSK's Oncology R&D Head: GSK2857916 'Proves We're Still Here And Serious'
Executive Summary
GSK's promising anti-BCMA antibody-drug conjugate GSK2857916 shows the UK group remains a serious contender in the innovative cancer space, its oncology R&D head tells Scrip.
You may also be interested in...
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product
The T-cell therapy company has been tipped as a potential leader in a potentially disruptive field as new data support wide application in cancer.